Journal Home
Search for

Volume 13, Issue 7, Pages 844-852 (July 2007)


View previous. 16 of 21 View next.

Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow Donor Program

Sergio GiraltCorresponding Author Informationemail address, Brent Logan, Douglas Rizzo, Mei-Jie Zhang, Karen Ballen, Christos Emmanouilides, Rajneesh Nath, Pablo Parker, David Porter, Brenda Sandmaier, Edmund K. Waller, Juliet Barker, Steven Pavletic, Daniel Weisdorf

Received 15 February 2007; accepted 25 March 2007. published online 26 May 2007.

Abstract 

To determine the long-term outcome of patients undergoing unrelated donor transplantation (URD) after a reduced intensity conditioning (RIC) regimen, we performed a retrospective analysis of the transplant outcomes of the first 5 years of RIC experience as reported to the National Marrow Donor Program (NMDP). Patients were included if they were older than 18 years and had undergone a URD transplant procured through the NMDP from January 1, 1996 until May 31, 2001, with an RIC regimen for a hematologic malignancy. The number of URDs performed using an RIC increased from 59 during 1996 to 1999, to 149 in the year 2000. RIC recipients were older (53 vs. 33 years) and had a higher likelihood of having advanced disease (81% vs. 51%) when compared to patients undergoing a myeloablative conditioning regimen during the same time period. The 5-year survival rate is 23% (95% confidence interval [CI]; 18, 28), whereas the 5 year incidence of progression/relapse is 43.4% (95% CI; 37,49). Prognostic factors for better overall survival on multivariate analysis were earlier disease stage, longer time to transplant from diagnosis, better HLA match, ≥90% performance score, and use of peripheral blood stem cells. This analysis demonstrates that long-term survival and disease control can be obtained with URD progenitor cell transplantation after RIC conditioning. However, only prospective trials will define the optimal role of this therapy in patients with hematologic malignancies. Therefore, URD transplantation with RIC should continue to be explored in the context of clinical trials.

The Nonmyeloablative Study Group, Center for International Blood and Marrow Transplant Research and the National Marrow Donor Program, Minneapolis, Minneapolis

Corresponding Author InformationCorrespondence and reprint requests: Sergio Giralt, MD, University of Texas M.D. Anderson Cancer Center, Blood and Marrow Transplant Program, 1515 Holcombe Boulevard, Houston, TX 77030.

PII: S1083-8791(07)00217-0

doi:10.1016/j.bbmt.2007.03.011


View previous. 16 of 21 View next.